Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japanese shares fall on profit-taking, pandemic worries

05/26/2021 | 10:51pm EST

TOKYO, May 27 (Reuters) - Japanese shares retreated on Thursday as investors trimmed their positions after a recent rally, while uncertainties about domestic economic growth due to a possible extension of COVID-19 emergency measures weighed on sentiment.

The Nikkei share average fell 0.69% to 28,445.25 by 0157 GMT, after a gain of 2.1% in five straight sessions. The broader Topix fell 0.39% to 1,913.32.

"We can say the market is down due to profit-taking, but there are also uncertainties ahead of us that are making investors cautions," said Takatoshi Itoshima, strategist at Pictet Asset Management.

"Overseas investors particularly are sceptical about the pace of Japan's COVID-19 vaccine rollouts, while economic outlook remains unclear as Japan is leaning toward extending the state of emergency."

Japan, which is slated to host the Tokyo 2020 Olympics in July, is struggling to contain a fourth wave of infections even as biggest cities are covered under emergency measures.

Tokyo governor Yuriko Koike on Wednesday sought the current state of emergency, originally set to be lifted at the end of May, to be extended for "about another month," while Osaka in the western region has made a similar request.

Investors want to see the impact of the MSCI's regular rebalancing, which will complete by the end of the session, as 29 Japanese shares will be excluded from its main index, Itoshima added.

Shippers and steel makers led the declines, falling 2.05% and 1.46%, respectively, while airliners , up 2.51%, gained the most among the 33 Tokyo Exchanges subindexes.

Astellas Pharma, up 3.26%, was the biggest percentage gainer among the top 30 core Topix names, followed by Keyence.

The underperformers among the Topix 30 were Recruit Holdings Co, down 2.83%, followed by Seven & i Holdings losing 2.48%. (Reporting by Junko Fujita and Kevin Buckland; editing by Uttaresh.V)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 0.45% 1782 End-of-day quote.11.79%
KEYENCE CORPORATION 0.07% 71010 End-of-day quote.22.43%
NIKKEI 225 1.00% 28029.57 Real-time Quote.1.13%
RECRUIT HOLDINGS CO., LTD. 2.17% 7191 End-of-day quote.66.42%
SEVEN & I HOLDINGS CO., LTD. 1.48% 4726 End-of-day quote.29.16%
All news about ASTELLAS PHARMA INC.
12/02Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
12/02Japanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
12/01ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
11/30ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
11/30WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
11/26ASTELLAS PHARMA : Annual Report 2021 is now available.
PU
11/25ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive..
PU
11/19ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19)
PU
11/14ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of..
PU
More news
Financials
Sales 2022 1 327 B 11 769 M 11 769 M
Net income 2022 183 B 1 623 M 1 623 M
Net cash 2022 380 B 3 369 M 3 369 M
P/E ratio 2022 17,9x
Yield 2022 2,81%
Capitalization 3 302 B 29 201 M 29 277 M
EV / Sales 2022 2,20x
EV / Sales 2023 1,93x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 782,00 JPY
Average target price 2 458,33 JPY
Spread / Average Target 38,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.11.79%29 201
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641